News
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...
StockStory.org on MSN1h
WeightWatchers (WW) Stock Trades Up, Here Is WhyShares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company ...
More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.
Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, ...
5d
Zacks.com on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...
Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results